Abstract
Recent evidence suggests that genetic variation is associated with individual variability in response to treatment with antipsychotics. Although numerous studies have been performed for identification of potential genetic variants affecting response to treatment, initial enthusiasm has been tempered by inconsistent results. Along with some specific methodological issues, another plausible explanation for such inconsistencies is lack of sensitivity of the phenotype (clinical measures) used to define response. In this paper, we review use of Imaging Genetics, a relatively new approach that combines genetic assessment with functional neuroimaging, to explore in vivo neurobiological effects of genetic variation. Moreover, we propose to use Imaging Genetics as a tool to evaluate and predict response to treatment with antipsychotics based on the individual genetic makeup.
Current Pharmaceutical Design
Title: Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics
Volume: 15 Issue: 22
Author(s): A. Di Giorgio, F. Sambataro and A. Bertolino
Affiliation:
Abstract: Recent evidence suggests that genetic variation is associated with individual variability in response to treatment with antipsychotics. Although numerous studies have been performed for identification of potential genetic variants affecting response to treatment, initial enthusiasm has been tempered by inconsistent results. Along with some specific methodological issues, another plausible explanation for such inconsistencies is lack of sensitivity of the phenotype (clinical measures) used to define response. In this paper, we review use of Imaging Genetics, a relatively new approach that combines genetic assessment with functional neuroimaging, to explore in vivo neurobiological effects of genetic variation. Moreover, we propose to use Imaging Genetics as a tool to evaluate and predict response to treatment with antipsychotics based on the individual genetic makeup.
Export Options
About this article
Cite this article as:
Di Giorgio A., Sambataro F. and Bertolino A., Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics, Current Pharmaceutical Design 2009; 15(22) . https://dx.doi.org/10.2174/138161209788957483
DOI https://dx.doi.org/10.2174/138161209788957483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Novel Treatments of Schizophrenia: Targeting the Neurotensin System
CNS & Neurological Disorders - Drug Targets Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets In Vitro Metabolism Studies of New Adenosine A Receptor Antagonists
Drug Metabolism Letters Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Progress in Understanding Basal Ganglia Dysfunction as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration
Current HIV Research Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry